Category: Regulations
-
Trial Underway Testing Sleep Apnea Stimulation Device
11 May 2015. A clinical trial testing an experimental neurostimulation device to treat obstructive sleep apnea implanted the device in its first two test patients. The trial is sponsored by ImThera Medical Inc. in San Diego, the developer of the aura6000 device being tested. Obstructive sleep apnea is a disorder where muscles in the throat…
-
Clinical Trial Testing West Nile Vaccine
7 May 2015. A vaccine for West Nile virus, a seasonal infection spread by mosquitoes, is being tested for safety in an early stage clinical trial. The vaccine, code-named HydroVax-001, is being developed in the lab of microbiologist Mark Slifka at Oregon Health and Science University in Beaverton and commercialized by Najit Technologies Inc., a…
-
Standard Devised to Cut Poultry Antibiotic Use
7 May 2015. An organization of school districts in the U.S., joined by the Pew Charitable Trusts and U.S. Department of Agriculture, wrote a set of guidelines to reduce the use of antibiotics in raising chickens destined for school feeding programs. Tyson Foods, the nation’s largest producer of chickens, also revealed today it is adopting…
-
Trial Underway Testing RNA Therapy for Rare Liver Disorder
5 May 2015. An early-stage clinical trial is testing a therapy derived from genetic material to treat alpha-1 antitrypsin deficiency, a rare inherited disease affecting the liver and lungs. The therapy, code-named ARC-AAT, is developed by Arrowhead Research Corporation, a biopharmaceutical company in Pasadena, California. Alpha-1 antitrypsin deficiency, or AATD, is caused by a mutation…
-
Stem Cells Treat Vision Disorders in Animal Tests
4 May 2015. Tests with lab rats of a therapy for degenerating retinas in the eyes, show the treatments derived from human embryonic stem cells can restore visual functions. Results of the treatments, developed by Cell Cure Neurosciences Ltd., are scheduled to be reported today by a research team from Oregon Health and Science University…
-
Trial Shows Multiple Sclerosis Drug Improves Optic Nerves
15 April 2015. A clinical trial testing a new therapy for multiple sclerosis shows the drug improves the performance of optic nerves in patients with acute optic neuritis, a condition highly associated with multiple sclerosis. Researchers from the biotechnology company Biogen present their findings next week at the annual meeting of American Academy of Neurology…
-
Trial Testing App to Manage Diabetes, Foot Ulcers
14 April 2015. A clinical trial is getting under way testing a smartphone app to help people with diabetes manage their condition, and in particular assess chronic foot ulcers associated with diabetes. The application is the work of an information technology and biomedical engineering team at Worcester Polytechnic Institute in Massachusetts, that described the system…
-
Alzheimer’s Drug Granted Orphan Status for Fragile X
9 April 2015. A new treatment in development for Alzheimer’s disease was designated an orphan drug for Fragile X syndrome, an inherited neurological disorder, by the U.S. Food and Drug Administration. Neurotrope BioScience Inc. in Newark, New Jersey, received the designation for its drug bryostatin, now in clinical testing to treat Alzheimer’s disease. Fragile X…
-
Trial Testing Mobile Apps for Mood Management
9 April 2015. A lab at Northwestern University medical school developed a collection of mobile apps for helping people cope with feelings of depression and anxiety, and is testing the apps as personalized interventions in a clinical trial. The study is led by David Mohr, director of Northwestern’s Center for Behavioral Intervention Technologies, who is…
-
Uninsured Patients Paying Far More for Cancer Drugs
8 April 2015. An analysis of cancer drug costs and reimbursement practices shows people without health insurance are paying much more for chemotherapy drugs than people covered under private insurance or Medicare. The team led by pharmacy professor Stacie Dusetzina at University of North Carolina in Chapel Hill published its findings in the April issue…